Novartis’ melanoma combo fails in PhIII
The study assessed investigational immunotherapy spartalizumab (PDR001) in combination with targeted therapies Tafinlar and Mekinist
Read More
Tag: ASCLEPIOS
- UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
- Saphnelo approved in the US for subcutaneous self‑administration
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
